Performing In-Depth Analysis of Lentiviral Cell Therapies: Luca Biasco, PhD


The director of research and development at AVROBIO discussed the molecular follow-up of cell therapies.

“We have developed a complex pipeline that starts from the bone marrow of the patients, and goes all the way to cellular processing, molecular processing, sequencing and computational analysis to deliver a comprehensive overview on how the engineered cells behave, and where they reside once we infuse them into the patient.”

AVROBIO is prioritizing molecular follow-up of lentiviral cell therapies in patients with lysosomal disease with the use of their new analytical pipeline that elucidates cell therapy destiny and distribution. Luca Biasco, PhD, director, research and development, AVROBIO, presented an overview of the pipeline at the 18th Annual WORLDSymposium, February 7-11, 2022 in San Diego, CA.

As part of the analytical pipeline, Biasco and colleagues conducted high-resolution cellular and molecular studies on bone marrow and peripheral blood before and after lentiviral cell therapy treatment. They analyzed subpopulations of bone marrow and peripheral blood cells via digital PCR-vector copy number and integration site analysis, as also used clonal tracking data to elucidate the dynamics and destiny of cell populations after gene therapy.

CGTLive spoke with Biasco to learn more about the analyses of the analytical pipeline. He discussed their methods and the importance of the analysis.

Biasco L, Baricordi C, Loperfido M, et al. High throughput monitoring of safety, potency and stability of gene therapy cell products in lysosomal disease patients. Presented at: 18th Annual WORLDSymposium. February 7-11, 2022; San Diego, CA. Poster #26
Related Videos
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
PJ Brooks, PhD
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
Carlos Moraes, PhD, on Understanding Mitochondrial Mutations for Neurodegenerative Diseases
© 2024 MJH Life Sciences

All rights reserved.